Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure

Journal of Hepatology

Volumn 64, Issue 3, 2016, Pages 574-582

  Mookerjee, Rajeshwar P ^a   Pavesi, Marco ^b   Thomsen, Karen Louise ^a   Mehta, Gautam ^a   MacNaughtan, Jane ^a   Bendtsen, Flemming ^c   Coenraad, Minneke ^d   Sperl, Jan ^e   Gines, Pere ^f,g,h   Moreau, Richard ^i,j,k,l   Arroyo, Vicente ^b   Jalan, Rajiv ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b European Foundation for the Study of Chronic Liver Failure (EF CLIF)   (Spain)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^f UNIVERSITY OF BARCELONA   (Spain)

^g INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^h INSTITUTO DE SALUD CARLOS III   (Spain)

ⁱ CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

^j UNIVERSITÉ PARIS DESCARTES   (France)

^k BEAUJON HOSPITAL   (France)

^l Laboratoire d'Excellence INFLAMEX   (France)

more..

Author keywords

Acute on chronic liver failure; Cirrhosis; Multi organ failure; Non selective beta blockers; Prognosis; Sepsis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; NADOLOL; PROPRANOLOL;

ACUTE ON CHRONIC LIVER FAILURE; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SAFETY; FEMALE; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK REDUCTION; SURVIVAL; TREATMENT OUTCOME; ACUTE-ON-CHRONIC LIVER FAILURE; AGED; BLOOD; COMPLICATION; STATISTICAL MODEL;

ACUTE-ON-CHRONIC LIVER FAILURE; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTE COUNT; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84958934083     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.10.018     Document Type: Article

References (29)

1. R. Jalan, and R. Williams Acute-on-chronic liver failure: pathophysiological basis of therapeutic options Blood Purif 20 2002 252 261
2. R. Moreau, R. Jalan, P. Gines, and et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis Gastroenterology 144 2013 1426 1437 37.e1-e9
3. R. Jalan, M. Pavesi, F. Saliba, and et al. The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure J Hepatol 62 2015 831 840
4. R. Jalan, F. Saliba, M. Pavesi, and et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure J Hepatol 61 2014 1038 1047
5. R. Jalan, V. Stadlbauer, S. Sen, L. Cheshire, Y.M. Chang, and R.P. Mookerjee Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure: a prospective cohort study Crit Care 1 2012 R227
6. R.P. Mookerjee, S. Sen, N.A. Davies, S.J. Hodges, R. Williams, and R. Jalan Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis Gut 52 2003 1182 1187
7. S. Naveau, S. Chollet-Martin, S. Dharancy, P. Mathurin, P. Jouet, M.A. Piquet, and et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acutealcoholic hepatitis Hepatology 39 2004 1390 1397
8. V. Arroyo, R. Moreau, and R. Jalan Acute-on-chronic liver failure: a new syndrome that will re-classify cirrhosis J Hepatol 62 2015 S131 S143
9. T. Sersté, C. Melot, C. Francoz, F. Durand, P.E. Rautou, D. Valla, and et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites Hepatology 52 2010 1017 1022
10. T. Sersté, C. Francoz, F. Durand, P.E. Rautou, C. Melot, D. Valla, and et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study J Hepatol 55 2011 794 799
11. M. Mandorfer, S. Bota, P. Schwabl, T. Bucsics, N. Pfisterer, M. Kruzik, and et al. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis Gastroenterology 146 2014 1680 1690
12. T. Sersté, H. Njimi, D. Degré, P. Deltenre, J. Schreiber, A. Lepida, and et al. The use of beta-blockers is associated with the occurrence of acute kidney injury in severe alcoholic hepatitis Liver Int 35 2015 1974 1982
13. J.A. Leithead, N. Rajoriya, N. Tehami, J. Hodson, B.K. Gunson, D. Tripathi, and et al. Non-selective β-blockers are associated with improved survival in patients with ascites listed for liver transplantation Gut 64 2015 1111 1119
14. R. de Franchis Baveno V Faculty Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension J Hepatol 53 2010 762 768
15. D. Lebrec, O. Nouel, J. Bernuau, M. Bouygues, B. Rueff, and J.P. Benhamou Propranolol in prevention of recurrent gastrointestinal bleeding in cirrhotic patients Lancet 1 1981 920 921
16. P.S. Ge, and B.A. Runyon Beta-blockers in cirrhosis: thank you for your attention J Hepatol 61 2014 451 452
17. B.S. Madsen, T. Havelund, and A. Krag Targeting the gut-liver axis in cirrhosis: antibiotics and non-selective β-blockers Adv Ther 30 2013 659 670
18. A. Morelli, C. Ertmer, M. Westphal, S. Rehberg, T. Kampmeier, S. Ligges, and et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial JAMA 310 2013 1683 1691
19. M. Worlicek, K. Knebel, H.J. Linde, L. Moleda, J. Schölmerich, R.H. Straub, and et al. Splanchnic sympathectomy prevents translocation and spreading of E coli but not S aureus in liver cirrhosis Gut 59 2010 1127 1134
20. J. Schäper, A. Wagner, F. Enigk, B. Brell, S.A. Mousa, H. Habazettl, and et al. Regional sympathetic blockade attenuates activation of intestinal macrophages and reduces gut barrier failure Anesthesiology 118 2013 134 142
21. I.J. Elenkov, D.G. Iezzoni, A. Daly, A.G. Harris, and G.P. Chrousos Cytokine dysregulation, inflammation and well-being Neuroimmunomodulation 12 2005 255 269
22. J. Pecivová, T. Macicková, A. Lojek, L. Gallová, M. Cíz, R. Nosál', and et al. Effect of carvedilol on reactive oxygen species and enzymes linking innate and adaptive immunity Neuro Endocrinol Lett 2006 160 163
23. N. Shah, D. Dhar, Mohammed F. El Zahraa, A. Habtesion, N.A. Davies, M. Jover-Cobos, and et al. Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expression J Hepatol 56 2012 1047 1053
24. J. Fernández, M. Navasa, R. Planas, S. Montoliu, D. Monfort, G. Soriano, and et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis Gastroenterology 133 2007 818 824
25. N.M. Bass, K.D. Mullen, A. Sanyal, F. Poordad, G. Neff, C.B. Leevy, and et al. Rifaximin treatment in hepatic encephalopathy N Engl J Med 362 2010 1071 1081
26. M. Senzolo, E. Cholongitas, P. Burra, G. Leandro, U. Thalheimer, D. Patch, and et al. Beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis Liver Int 29 2009 1189 1193
27. N. Kimer, M. Feineis, S. Møller, and F. Bendtsen Beta-blockers in cirrhosis and refractory ascites: a retrospective cohort study and review of the literature Scand J Gastroenterol 50 2015 129 137
28. J.S. Bajaj, S.M. Ratliff, D.M. Heuman, and K.L. Lapane Non-selective beta-blockers are not associated with serious infections in veterans with cirrhosis Aliment Pharmacol Ther 38 2013 407 414
29. T. Gustot, J. Fernandez, E. Garcia, and et al. Clinical course of acute-on-chronic liver failure and effects on prognosis Hepatology 62 2015 243 252